financetom
Business
financetom
/
Business
/
Google, TPG Rise Climate Invest in Intersect Power, Form Partnership for Industrial Parks in US
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Google, TPG Rise Climate Invest in Intersect Power, Form Partnership for Industrial Parks in US
Dec 10, 2024 7:39 AM

10:20 AM EST, 12/10/2024 (MT Newswires) -- Alphabet's (GOOG, GOOGL) Google ( GOOG ) and TPG Rise Climate led a funding round that raised more than $800 million for Intersect Power, the clean energy company said Tuesday.

The parties are also collaborating to build industrial parks in the US with gigawatts of data center capacity next to clean energy plants to reduce the timeline to operation and the amount of new transmission required, Google ( GOOG ) and Intersect added.

Under the terms, Intersect will construct new clean energy facilities while the technology giant will provide offtake through newly built data center campuses as anchor tenant in co-located industrial parks, Intersect said, adding it targets $20 billion in renewable power infrastructure investment by the end of the decade.

The first co-located clean energy project is anticipated to be operational by 2026 and fully completed in 2027, according to Google ( GOOG ) and Intersect.

Intersect Power is a portfolio company of TPG Rise Climate. Other investors that participated in the funding round were Climate Adaptive Infrastructure and Greenbelt Capital Partners, Intersect said.

Alphabet's stock rose over 5% in recent Tuesday trading.

Price: 186.31, Change: +9.21, Percent Change: +5.20

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Karbon Acquires Aider to Deliver the Future of AI-Powered Accounting and Bookkeeping
Karbon Acquires Aider to Deliver the Future of AI-Powered Accounting and Bookkeeping
Sep 30, 2025
SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Karbon, the global leader in practice management software for accounting, bookkeeping, tax and audit firms, today announced its acquisition of Aider, a pioneer in AI-powered advisory and reporting technology. The acquisition accelerates Karbon’s vision to transform the accounting profession through AI. Aider’s cutting-edge solution is already trusted by firms across the United...
Terra Innovatum and GSR III Acquisition Corp. Remind Shareholders to Vote and Approve the Business Combination Prior to the October 7 Extraordinary General Meeting of Shareholders
Terra Innovatum and GSR III Acquisition Corp. Remind Shareholders to Vote and Approve the Business Combination Prior to the October 7 Extraordinary General Meeting of Shareholders
Sep 30, 2025
GSRT shareholders are encouraged to use their voice and vote FOR the business combination and other proposals ahead of the deadline on October 6, 2025, at 11:59 p.m. ET Shareholders as of September 15, 2025, should vote their shares even if they no longer own them NEW YORK and AUSTIN, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Terra Innovatum Srl...
Market Chatter: UBS, Switzerland Consider Lower Capital Rules
Market Chatter: UBS, Switzerland Consider Lower Capital Rules
Sep 30, 2025
07:57 AM EDT, 09/30/2025 (MT Newswires) -- UBS (UBS) and Switzerland are privately open to a compromise on new capital rules, potentially clearing a path for lower requirements acceptable to both sides, Reuters reported Tuesday, citing people familiar with the situation. Bern could accept trimming the extra capital burden to $15 billion from the $24 billion plan from June, a...
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
Sep 30, 2025
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease. Four key value-driving milestones are expected within 18 months, including clinical proof of concept in multiple indications. Estimated cash runway for combined company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved